Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Mount Sinai Medical Center, NY
mi
from
New York, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Mount Sinai Medical Center, NY
mi
from
New York, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
Syracuse, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.
mi
from
Syracuse, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
State University of New York Upstate Medical University
mi
from
Syracuse, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Syracuse
mi
from
Syracuse, NY
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Lineberger Comprehensive Cancer Center, UNC
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Durham
mi
from
Durham, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Duke Comprehensive Cancer Center
mi
from
Durham, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
CCOP - Southeast Cancer Control Consortium
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Arthur G. James Cancer Hospital - Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Rhode Island Hospital
mi
from
Providence, RI
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Memphis
mi
from
Memphis, TN
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
University of Tennessee, Memphis Cancer Center
mi
from
Memphis, TN
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
University of Tennessee, Memphis Cancer Center
mi
from
Memphis, TN
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Vermont Cancer Center
mi
from
Burlington, VT
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Vermont Cancer Center
mi
from
Burlington, VT
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - White River Junction
mi
from
White River Junction, VT
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Richmond
mi
from
Richmond, VA
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Richmond
mi
from
Richmond, VA
Click here to add this to my saved trials
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  7/19/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Gemcitabine Plus Radiation Therapy in Treating Patients With Pancreatic Cancer
Phase II Chemoradiation Trial Using Gemcitabine in Patients With Locoregional Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 7/19/2016
MBCCOP - Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of California San Diego Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
UCSF Cancer Center and Cancer Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
CCOP - Christiana Care Health Services
mi
from
Wilmington, DE
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Vincent T. Lombardi Cancer Research Center, Georgetown University
mi
from
Washington,
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Walter Reed Army Medical Center
mi
from
Washington,
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Illinois at Chicago Health Sciences Center
mi
from
Chicago, IL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Illinois at Chicago Health Sciences Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Chicago Westside Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Togus
mi
from
Togus, ME
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
University of Massachusetts Memorial Medical Center
mi
from
Worcester, MA
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Columbia (Truman Memorial)
mi
from
Columbia, MO
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Ellis Fischel Cancer Center - Columbia
mi
from
Columbia, MO
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Ellis Fischel Cancer Center - Columbia
mi
from
Columbia, MO
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Omaha
mi
from
Omaha, NE
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Omaha
mi
from
Omaha, NE
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
CCOP - Southern Nevada Cancer Research Foundation
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Veterans Affairs Medical Center - Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
CCOP - North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
North Shore University Hospital
mi
from
Manhasset, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
North Shore University Hospital
mi
from
Manhasset, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  7/19/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer
Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 7/19/2016
The New York Presbyterian Hospital - Cornell Campus
mi
from
New York, NY
Click here to add this to my saved trials